Next-Generation Genome Screening is Step toward Precision Cancer Medicine for Lung Cancer

“Precision cancer medicine has taken a strong step forward at the Ohio State University Comprehensive Cancer Center. The technology, known as next generation “multiplex” gene sequencing, analyzes 50-plus genes in DNA extracted from a tumor biopsy for particular genetic mutations. Previous technology required pathologists to analyze one mutation per tissue sample. This second-generation genome sequencing assesses more than 2,500 mutations in a single reaction.”